InsiderClue
Stocks · Health care · Surgical & Medical Instruments & Apparatus

SpyGlass Pharma, Inc.

SGP Clue Score33
United States Fiscal year ends December CIK 0001778922
$24.92 +1.22% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $24.92 +17.44% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 6 Feb 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−27.1Net income−29.2EPS, diluted−16.31Fiscal year 2025Operating income−41.4Net income−39.9EPS, diluted−17.98
FY2024FY2025
Operating income −27.1 −41.4
Net income −29.2 −39.9
Growth
EPS, diluted −16.31 −17.98
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−22.0Capital expenditure−2.0Free cash flow−24.0Buybacks0.0Fiscal year 2025Operating cash flow−32.7Capital expenditure−0.8Free cash flow−33.5Buybacks−1.5
FY2024FY2025
Operating cash flow −22.0 −32.7
Capital expenditure −2.0 −0.8
Free cash flow −24.0 −33.5
Growth
Buybacks 0.0 −1.5

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash16.3Shareholders’ equity−60.5Fiscal year 2025Cash96.4Shareholders’ equity−98.8
FY2024FY2025
Cash 16.3 96.4
Shareholders’ equity −60.5 −98.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
−125.1% −34.4%
Balance and payout
48.2% 8.8%